[Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China]

Ai Zheng. 2009 Dec;28(12):1310-6. doi: 10.5732/cjc.009.10230.
[Article in Chinese]

Abstract

Background and objective: Even though most breast cancers occur in postmenopausal women in western countries, age <35 is one of the prognostic factors. This study was to compare the clinicopathologic characteristics and prognosis between premenopausal breast cancer patients aged of <35 and > or =35 in south China, and to explore the prognostic factors.

Methods: A total of 905 consecutive premenopausal patients were evaluated, with first diagnosis of breast cancer referred to surgery at the Sun Yat-sen University Cancer Center from October 2003 to December 2006. The clinicopathologic factors and the survival rates between the very young group(aged of <35 at diagnosis) and the non-young group(aged of > or =35 at diagnosis) were retrospectively compared.

Results: The overall median follow-up time was 27.77 months. The 3-year disease-free survival rate was significantly lower (78.0% vs. 89.1%, P<0.001) and the 3-year survival rate relatively lower(94.3% vs. 96.8%, P=0.10) in the very young group than in the non-young group. In addition, the 3-year survival and disease-free survival rates were significantly lower in the very young group with HR (hormone receptor)-positive than in the non-young group (P<0.05). The univariate and multivariate analysis of clinicopathologic characteristics between two groups showed that age <35 at diagnosis, axillary lymph node involvement, presence of vascular invasion, and high expression of Ki67 were risk factors for recurrence.

Conclusion: Compared with non-young premenopausal patients, very young breast patients with HR-positive cancer have a worse outcome.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adult
  • Age Factors
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / blood
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / therapy*
  • China
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Ki-67 Antigen / blood
  • Lymphatic Metastasis
  • Mastectomy / methods
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Neoplastic Cells, Circulating
  • Premenopause
  • Proportional Hazards Models
  • Radiotherapy, High-Energy
  • Receptors, Estrogen / blood
  • Receptors, Progesterone / blood
  • Retrospective Studies
  • Survival Rate
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Ki-67 Antigen
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen